​

Fate Therapeutics Ownership | Who Owns Fate Therapeutics?

OverviewForecastRevenueFinancialsChart

Fate Therapeutics Ownership Summary

Fate Therapeutics is owned by 67.18% institutional investors, 1.77% insiders, and 31.05% retail investors. Redmile group is the largest institutional shareholder, holding 10.86% of FATE shares. BB Biotech AG Ord is the top mutual fund, with 4.25% of its assets in Fate Therapeutics shares.

FATE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockFate Therapeutics67.18%1.77%31.05%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Redmile group12.87M10.86%$16.22M
Blackrock10.12M10.01%$33.18M
Blackrock funding, inc. /de10.68M9.01%$13.46M
Boxer capital8.22M8.13%$26.95M
Vanguard group8.80M7.42%$11.09M
Wilshire advisors8.49M7.16%$10.69M
Johnson & johnson3.38M2.85%$4.26M
Acadian asset management2.71M2.29%$3.41M
Geode capital management2.53M2.13%$3.19M
Vestal point capital, lp2.52M2.12%$3.17M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Wilshire advisors8.49M27.71%$10.69M
Redmile group12.87M1.58%$16.22M
Boxer capital8.22M1.42%$26.95M
Johnson & johnson3.38M0.85%$4.26M
Bruce729.19K0.28%$918.78K
Knott david m jr365.00K0.19%$459.90K
Vestal point capital, lp2.52M0.14%$3.17M
Tang capital management1.87M0.09%$2.35M
Artal group1.03M0.09%$3.39M
Privium fund management b.v.333.22K0.08%$419.86K

Top Buyers

HolderShares% AssetsChange
Wilshire advisors8.49M27.71%8.49M
Renaissance1.26M0.00%1.05M
Blackrock10.12M0.00%1.02M
Two sigma investments, lp900.76K0.00%672.35K
Artal group1.03M0.09%672.19K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---5.57M
Bellevue group---4.84M
Deerfield management company, l.p. (series c)---3.56M
Ecor1 capital---3.05M
Suvretta capital management---2.56M

New Positions

HolderShares% AssetsChangeValue
Quadrature capital377.36K0.01%377.36K$475.47K
Knott david m jr365.00K0.19%365.00K$459.90K
Man group219.66K0.00%219.66K$276.77K
Deutsche bank ag\157.16K0.00%157.16K$198.02K
Atom investors lp110.23K0.01%110.23K$138.89K

Sold Out

HolderChange
Mather group, llc.-5.00
Innealta capital-9.00
Chris bulman-10.00
Nelson, van denburg & campbell wealth management group-17.00
Evermay wealth management-25.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025135-3.57%79,628,3630.09%671.49%62-12.68%36-12.20%
Jun 30, 20251384.55%79,496,955-17.58%671.01%7022.81%40-2.44%
Mar 31, 20256-96.23%21,342,655-78.99%180.25%2-97.40%1-97.92%
Dec 31, 2024157-3.68%101,473,772-11.49%860.91%7620.63%47-16.07%
Sep 30, 2024163-9.94%114,640,778-6.17%970.67%63-33.68%5718.75%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord4.84M4.25%-
Vanguard US Total Market Shares ETF3.05M2.66%-
Vanguard Total Stock Mkt Idx Inv2.98M2.60%-65.80K
iShares Russell 2000 ETF2.59M2.25%-
Vanguard Strategic Equity Inv2.54M2.22%-
SPDR® S&P Biotech ETF2.34M2.06%33.31K
Vanguard Explorer Inv1.27M1.11%-
Fidelity Small Cap Index1.10M0.95%65.94K
Vanguard Institutional Extnd Mkt Idx Tr964.45K0.84%-439.47K
BlackRock Advantage Small Cap Core Instl945.76K0.82%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 04, 2025TAHL CINDY See RemarksSell$9.57K
Aug 04, 2025Valamehr Bahram President and CEOSell$15.40K
Jan 10, 2025Bressi Jerome Charles See RemarksSell$9.27K
Jan 10, 2025TAHL CINDY See RemarksSell$8.76K
Jan 10, 2025Valamehr Bahram President and CEOSell$13.41K

Insider Transactions Trends

DateBuySell
2025 Q4--
2025 Q3-2
2025 Q2--
2025 Q1-3
2024 Q411

FATE Ownership FAQ

Who Owns Fate Therapeutics?

Fate Therapeutics shareholders are primarily institutional investors at 67.18%, followed by 1.77% insiders and 31.05% retail investors. The average institutional ownership in Fate Therapeutics's industry, Biotech Stocks , is 45.22%, which Fate Therapeutics exceeds.

Who owns the most shares of Fate Therapeutics?

Fate Therapeutics’s largest shareholders are Redmile group (12.87M shares, 10.86%), Blackrock (10.12M shares, 10.01%), and Blackrock funding, inc. /de (10.68M shares, 9.01%). Together, they hold 29.88% of Fate Therapeutics’s total shares outstanding.

Does Blackrock own Fate Therapeutics?

Yes, BlackRock owns 10.01% of Fate Therapeutics, totaling 10.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 33.18M$. In the last quarter, BlackRock increased its holdings by 1.02M shares, a 11.17% change.

Who is Fate Therapeutics’s biggest shareholder by percentage of total assets invested?

Wilshire advisors is Fate Therapeutics’s biggest shareholder by percentage of total assets invested, with 27.71% of its assets in 8.49M Fate Therapeutics shares, valued at 10.69M$.

Who is the top mutual fund holder of Fate Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Fate Therapeutics shares, with 4.25% of its total shares outstanding invested in 4.84M Fate Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools